feedback

Course Director

William G. Wierda, MD, PhD
William G. Wierda, MD, PhD

The University of Texas MD Anderson Cancer Center
Houston, Texas

Faculty

Matthew S. Davids
Matthew S. Davids, MD, MMSc

Dana-Farber Cancer Institute
Boston, Massachusetts

Asher A. Chanan-Khan
Asher A. Chanan-Khan, MD

Mayo Clinic, Jacksonville, Florida
Mayo Clinic College of Medicine
Jacksonville, Florida

Accredited by

Penn State College of Medicine / Medical Learning Institute, Inc.

Activity Details

Credit Types:CME / CPE / CE
Credit Amount:2.0 Credits
Release Date:2017-Jun-21
Expiration Date:2018-Jun-20
Estimated Time for Completion:2 hours
Registration Required:No
Cost:Free of charge
Activity Description and Educational Objectives
This activity based on a recent live symposium held at the XVII International Workshop on Chronic Lymphocytic Leukemia (iwCLL 2017) offers professionals a “Master Class” on the meaning of precision medicine in CLL in the modern era, including insights on how to select and sequence novel agent classes (BTK inhibitors, Bcl2 -targeting agents, and next-generation anti-CD20 antibodies), while addressing key practical considerations such as prognostic assessment and adverse event management. In addition, our panel of experts provides case-based illustrations of a more tailored approach to therapy in CLL and reviews important ongoing clinical trials that may further crystallize the use of newer therapeutics in the CLL setting.

Upon completion of this activity, participants will be able to:
  • Describe the implications of clinically relevant baseline factors in the CLL setting, including advanced age, functional status, and molecular prognostic factors
  • Select individualized therapy for patients with newly diagnosed CLL, including regimens with novel components or treatment in the context of a clinical trial
  • Recommend the optimal therapeutic sequence for patients with CLL initiating treatment across the disease continuum, including in patients presenting with high-risk features
  • Manage safety considerations in patients with CLL receiving novel treatment regimens, including BTK or Bcl-2 inhibitors, or next-generation antibodies

Target Audience
This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, nurses, pharmacists, and other healthcare professionals who manage patients with chronic lymphocytic leukemia.

Nursing Education Purpose Statement
The purpose of this activity is to improve knowledge and competence of nurses concerning the treatment of CLL.

Requirements for Successful Completion
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 80% or higher is needed to obtain CME credit and 70% or higher to obtain CE/CPE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CE/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: June 21, 2017 - June 20, 2018
Time to Complete: 120 minutes

Faculty & Disclosure / Conflict of Interest Policy
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Penn State College of Medicine and Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Course Director and Moderator
William G. Wierda, MD, PhD
D.B. Lane Cancer Research Distinguished Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

William G. Wierda, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant for AbbVie; Celgene Corporation; Emergent BioSolutions Inc.; Genentech/F. Hoffmann-La Roche; Gilead Sciences, Inc.; GlaxoSmithKline/Novartis Pharmaceuticals Corporation; Merck & Co., Inc.; Pharmacyclics; Sanofi; and Sanofi Genzyme.
Grant/Research Support from AbbVie; Acerta Pharma; Emergent BioSolutions Inc.; Genentech, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline/Novartis Pharmaceuticals Corporation; Janssen Pharmaceuticals, Inc.; Juno Therapeutics; Karyopharm Therapeutics Inc.; Kite Pharma; and Pharmacyclics.

William G. Wierda, MD, PhD, does not intend to discuss any non-FDA-approved or investigational use of any products/devices.

Faculty
Matthew S. Davids, MD, MMSc
Assistant Professor of Medicine
Dana-Farber Cancer Institute
Boston, Massachusetts

Matthew S. Davids, MD, MMSc, has a financial interest/relationship or affiliation in the form of:
Consultant for AbbVie Inc.; Celgene Corporation; Genentech, Inc.; Gilead; Incyte Corporation; and Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.
Grant/Research Support from Genentech, Inc.; Infinity Pharmaceuticals, Inc.; Pharmacyclics LLC, an AbbVie Company; and TG Therapeutics, Inc.

Matthew S. Davids MD, MMSc, does not intend to discuss any non-FDA-approved or investigational use of any products/devices.

Asher A. Chanan-Khan, MD
Chair, Division of Hematology/Oncology
Department of Internal Medicine
Mayo Clinic, Jacksonville, Florida
Professor of Medicine and Oncology
Mayo Clinic College of Medicine
Jacksonville, Florida

Asher A. Chanan-Khan, MD, has no financial interests/relationships or affiliations in relation to this activity.

Asher A. Chanan-Khan, MD, does not intend to discuss any non-FDA-approved or investigational use of any products/devices.

Nurse Reviewer
Bobbie Perrin, RN, OCN
Harrington Cancer Center
Amarillo, Texas

Bobbie Perrin, RN, OCN, has no financial interests/relationships or affiliations in relation to this activity.

CPE Reviewer
Patricia A. Ensor, RPh, MBA
Kantar Health
Horsham, PA

Patricia A. Ensor, RPh, MBA, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director
Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

The associates of Medical Learning Institute, Inc. do not have any financial relationships or relationships to products or devices with any commercial interest.

Disclaimer
The information provided at this CME/CE/CPE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G6097 - 18 - T.

Nurses
Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider Number 15106, for 2.0 contact hour(s).

Pharmacists
ACPEThe Medical Learning Institute, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Completion of this application-based activity provides for 2.0 contact hours (0.2 CEUs) of continuing pharmacy education credit. The Universal Activity Number for this activity is 0468‑9999‑17-008‑H01-P.

Providership
This CME/CE/CPE activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education; this activity is also co-provided by Medical Learning Institute, Inc.

Support
This activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.

Copyright © 2000-2017, PeerView Press

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.